Peter Maag Sells 10,000 Shares of CareDx, Inc. (NASDAQ:CDNA) Stock

CareDx, Inc. (NASDAQ:CDNA - Get Free Report) Director Peter Maag sold 10,000 shares of the stock in a transaction on Monday, July 7th. The shares were sold at an average price of $18.58, for a total transaction of $185,800.00. Following the transaction, the director owned 308,846 shares in the company, valued at $5,738,358.68. This trade represents a 3.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Peter Maag also recently made the following trade(s):

• On Tuesday, June 17th, Peter Maag sold 10,000 shares of CareDx stock. The shares were sold at an average price of $19.24, for a total transaction of $192,400.00.
• On Wednesday, April 30th, Peter Maag sold 13,281 shares of CareDx stock. The stock was sold at an average price of $17.23, for a total transaction of $228,831.63.

CareDx Stock Down 1.8%

CDNA traded down $0.37 during midday trading on Friday, hitting $20.26. 407,534 shares of the company were exchanged, compared to its average volume of 921,544. CareDx, Inc. has a 1-year low of $14.09 and a 1-year high of $34.84. The firm's 50 day moving average price is $17.99 and its 200-day moving average price is $19.71. The firm has a market capitalization of $1.13 billion, a P/E ratio of 17.57 and a beta of 2.19.

CareDx (NASDAQ:CDNA - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The company reported $0.09 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.06 by $0.03. The firm had revenue of $84.69 million for the quarter, compared to the consensus estimate of $84.56 million. CareDx had a net margin of 19.79% and a return on equity of 21.16%. The business's revenue for the quarter was up 17.6% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.03) EPS. On average, sell-side analysts predict that CareDx, Inc. will post -0.9 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on CDNA shares. Stephens reissued an "overweight" rating and set a $40.00 target price on shares of CareDx in a research note on Monday, May 5th. Wall Street Zen downgraded shares of CareDx from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. HC Wainwright reaffirmed a "neutral" rating and set a $25.00 price objective on shares of CareDx in a research report on Monday, May 5th. Finally, The Goldman Sachs Group lowered their price objective on shares of CareDx from $34.00 to $26.00 and set a "buy" rating on the stock in a research report on Thursday, April 17th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $30.33.

Institutional Trading of CareDx

A number of institutional investors have recently made changes to their positions in CDNA. Sterling Capital Management LLC raised its holdings in CareDx by 771.2% in the fourth quarter. Sterling Capital Management LLC now owns 1,272 shares of the company's stock worth $27,000 after purchasing an additional 1,126 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in CareDx by 553.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,922 shares of the company's stock worth $84,000 after purchasing an additional 3,322 shares during the last quarter. State of Wyoming purchased a new position in CareDx in the fourth quarter worth about $91,000. PNC Financial Services Group Inc. lifted its position in shares of CareDx by 20,200.0% during the 1st quarter. PNC Financial Services Group Inc. now owns 4,466 shares of the company's stock valued at $79,000 after buying an additional 4,444 shares in the last quarter. Finally, Morse Asset Management Inc purchased a new position in shares of CareDx during the 1st quarter valued at about $103,000.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.